NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
Press release content from Accesswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Pascal Nigen News
Page 2 - Pascal Nigen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Nigen. Real-time updates on events, politics, business and more.
NLS Pharmaceutics AG: NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience (Mazindol ER) in Patients with Narcolepsy
Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trialSafety and tolerability
Source: finanznachrichten.de
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
Press release content from Accesswire. The AP news staff was not involved in its creation.
Source: apnews.com
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
Source: finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and
Alex Zwyer Kostenloser Wertpapierhandel Cindy Rizzo Pascal Nigen Alpha Bronze International Narcolepsy Webinar
Source: finanznachrichten.de